2020 ICD-10-CM Diagnosis Code C83.1

Mantle cell lymphoma

    2016 2017 2018 2019 2020 Non-Billable/Non-Specific Code
  • C83.1 should not be used for reimbursement purposes as there are multiple codes below it that contain a greater level of detail.
  • The 2020 edition of ICD-10-CM C83.1 became effective on October 1, 2019.
  • This is the American ICD-10-CM version of C83.1 - other international versions of ICD-10 C83.1 may differ.
Applicable To
  • Centrocytic lymphoma
  • Malignant lymphomatous polyposis
The following code(s) above C83.1 contain annotation back-references
Annotation Back-References
In this context, annotation back-references refer to codes that contain:
  • Applicable To annotations, or
  • Code Also annotations, or
  • Code First annotations, or
  • Excludes1 annotations, or
  • Excludes2 annotations, or
  • Includes annotations, or
  • Note annotations, or
  • Use Additional annotations
that may be applicable to C83.1:
  • C00-D49
    2020 ICD-10-CM Range C00-D49

    Neoplasms

    Note
    • Functional activity
    • All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm.
    • Morphology [Histology]
    • Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, etc. The Table of Neoplasms should be used to identify the correct topography code. In a few cases, such as for malignant melanoma and certain neuroendocrine tumors, the morphology (histologic type) is included in the category and codes.
    • Primary malignant neoplasms overlapping site boundaries
    • A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous, such as tumors in different quadrants of the same breast, codes for each site should be assigned.
    • Malignant neoplasm of ectopic tissue
    • Malignant neoplasms of ectopic tissue are to be coded to the site mentioned, e.g., ectopic pancreatic malignant neoplasms are coded to pancreas, unspecified (C25.9).
    Neoplasms
  • C81-C96
    2020 ICD-10-CM Range C81-C96

    Malignant neoplasms of lymphoid, hematopoietic and related tissue

    Type 2 Excludes
    • Kaposi's sarcoma of lymph nodes (C46.3)
    • secondary and unspecified neoplasm of lymph nodes (C77.-)
    • secondary neoplasm of bone marrow (C79.52)
    • secondary neoplasm of spleen (C78.89)
    Malignant neoplasms of lymphoid, hematopoietic and related tissue
  • C83
    ICD-10-CM Diagnosis Code C83

    Non-follicular lymphoma

      2016 2017 2018 2019 2020 Non-Billable/Non-Specific Code
    Type 1 Excludes
    • personal history of non-Hodgkin lymphoma (Z85.72)
    Non-follicular lymphoma
Clinical Information
  • A clinico-pathological entity reflecting the multiple polyps throughout the gastrointestinal tract created as a result of involvement by a non-hodgkin lymphoma. Typically, mantle cell lymphomas involving the gastrointestinal tract give rise to multifocal lymphomatous polyposis. Importantly, other histologic subtypes of non-hodgkin lymphoma can also produce this clinico-pathological entity. (who, 2000)
  • A form of non-hodgkin lymphoma having a usually diffuse pattern with both small and medium lymphocytes and small cleaved cells. It accounts for about 5% of adult non-hodgkin lymphomas in the United States and europe. The majority of mantle-cell lymphomas are associated with a t(11;14) translocation resulting in overexpression of the cyclin d1 gene (genes, bcl-1).
  • A group of cancers of the lymphoid system, including acute lymphoblastic leukemia, b-cell lymphoma, burkitt's lymphoma, diffuse cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, lymphoblastic lymphoma, mantle cell lymphoma, mycosis fungoides, post-transplantation lymphoproliferative disorder, small non-cleaved cell lymphoma, and t-cell lymphoma.
  • An aggressive (fast-growing) type of b-cell non-hodgkin lymphoma that usually occurs in middle-aged or older adults. It is marked by small- to medium-size cancer cells that may be in the lymph nodes, spleen, bone marrow, blood, and gastrointestinal system.
  • An aggressive, usually diffuse non-hodgkin lymphoma composed of small to medium sized b-lymphocytes (centrocytes). Most patients present with advanced stage disease with lymphadenopathy, hepatosplenomegaly, and bone marrow involvement. The gastrointestinal tract is the most commonly affected extranodal site by this type of non-hodgkin lymphoma. The vast majority of cases express the t(11;14)(q13;q32) resulting in the rearrangement of the bcl-1 gene and the overexpression of cyclin d1 mrna.
  • Any of a group of malignant tumors of lymphoid tissue that differ from hodgkin disease, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant reed-sternberg cells, a characteristic of hodgkin's disease.
  • Any of a large group of cancers of lymphocytes (white blood cells). Nhls can occur at any age and are often marked by lymph nodes that are larger than normal, fever, and weight loss. There are many different types of nhl. These types can be divided into aggressive (fast-growing) and indolent (slow-growing) types, and they can be formed from either b-cells or t-cells. B-cell nhls include burkitt lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma (cll/sll), diffuse large b-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, precursor b-lymphoblastic lymphoma, and mantle cell lymphoma. T-cell nhls include mycosis fungoides, anaplastic large cell lymphoma, and precursor t-lymphoblastic lymphoma. Lymphomas that occur after bone marrow or stem cell transplantation are usually b-cell nhls. Prognosis and treatment depend on the stage and type of disease.
  • Characterized by malignant lymphomas; clinically similar to hodgkin's disease, except that the lymphomas seen in this disease are initially more widespread; most common manifestation is painless enlargement of one or more peripheral lymph nodes.
  • Distinct from hodgkin lymphoma both morphologically and biologically, non-hodgkin lymphoma (nhl) is characterized by the absence of reed-sternberg cells, can occur at any age, and usually presents as a localized or generalized lymphadenopathy associated with fever and weight loss. The clinical course varies according to the morphologic type. Nhl is clinically classified as indolent, aggressive, or having a variable clinical course. Nhl can be of b-or t-/nk-cell lineage.
Code History
  • 2016 (effective 10/1/2015): New code (first year of non-draft ICD-10-CM)
  • 2017 (effective 10/1/2016): No change
  • 2018 (effective 10/1/2017): No change
  • 2019 (effective 10/1/2018): No change
  • 2020 (effective 10/1/2019): No change

Diagnosis Index entries containing back-references to C83.1:
  • Lymphoma (of) (malignant) C85.90
    ICD-10-CM Diagnosis Code C85.90

    Non-Hodgkin lymphoma, unspecified, unspecified site

      2016 2017 2018 2019 2020 Billable/Specific Code
    • centrocytic C83.1-
    • mantle cell C83.1-
  • Polyposis - see also Polyp
    • malignant lymphomatous C83.1-

ICD-10-CM Codes Adjacent To C83.1
C83.00 …… unspecified site
C83.01 …… lymph nodes of head, face, and neck
C83.02 …… intrathoracic lymph nodes
C83.03 …… intra-abdominal lymph nodes
C83.04 …… lymph nodes of axilla and upper limb
C83.05 …… lymph nodes of inguinal region and lower limb
C83.06 …… intrapelvic lymph nodes
C83.07 …… spleen
C83.08 …… lymph nodes of multiple sites
C83.09 …… extranodal and solid organ sites
C83.1 Mantle cell lymphoma
C83.10 …… unspecified site
C83.11 …… lymph nodes of head, face, and neck
C83.12 …… intrathoracic lymph nodes
C83.13 …… intra-abdominal lymph nodes
C83.14 …… lymph nodes of axilla and upper limb
C83.15 …… lymph nodes of inguinal region and lower limb
C83.16 …… intrapelvic lymph nodes
C83.17 …… spleen
C83.18 …… lymph nodes of multiple sites
C83.19 …… extranodal and solid organ sites

Reimbursement claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes.